Serotonin and noradrenaline involvement in urinary incontinence, depression and pain: Scientific basis for overlapping clinical efficacy from a single drug, duloxetine

International Journal of Clinical Practice

Volumn 61, Issue 8, 2007, Pages 1349-1355

  Thor, K B ^a,b   Kirby, M ^c,f   Viktrup, L ^d,e  

^a DUKE UNIVERSITY   (United States)

^b Urogenix Inc   (United States)

^c Hertfordshire Primary Care Research Network   (United Kingdom)

^d ELI LILLY AND COMPANY   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DULOXETINE; NEUROTRANSMITTER; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; PLACEBO; SEROTONIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ADRENAL MEDULLA; ANOREXIA; ANORGASMIA; APPETITE; BRAIN CORTEX; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERHIDROSIS; INSOMNIA; LIBIDO DISORDER; MAJOR DEPRESSION; NAUSEA; NEUROPATHIC PAIN; NEUROTRANSMISSION; NOCICEPTION; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; STRESS INCONTINENCE; SWEATING; SYNAPSE; SYNAPTIC TRANSMISSION; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT FUNCTION; WEAKNESS; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DIABETIC NEUROPATHIES; FEMALE; HUMANS; MALE; NOREPINEPHRINE; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; THIOPHENES; TREATMENT OUTCOME; URINARY INCONTINENCE, STRESS;

EID: 34447322530     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01433.x     Document Type: Review

References (57)

1. Vigod SN, Stewart DE. Major depression in female urinary incontinence. Psychosomatics 2006 47 : 147 51.
2. Melville JL, Delaney K, Newton K, Katon W. Incontinence severity and major depression in incontinent women. Obstet Gynecol 2005 106 : 585 92.
3. Steers WD, Herschorn S, Kreder KJ et al. Duloxetine compared with placebo for treating women with symptoms of overactive bladder. BJU Int 2007 19 May [Epub ahead of print].
4. Katona C, Peveler R, Dowrick C et al. Pain symptoms in depression: definition and clinical significance. Clin Med 2005 5 : 390 5.
5. Thompson JH. Serotonin and the alimentary tract. Res Commun Chem Pathol Pharmacol 1971 2 : 687 781.
6. Hanyu S, Iwanaga T, Kano K, Fujita T. Distribution of serotonin-immunoreactive paraneurons in the lower urinary tract of dogs. Am J Anat 1987 180 : 349 56.
7. Vialli M, Erspamer V. Richerche sul secreto delle cellule enterochromaffine. IX. Intorno alla natura chimica della sostanza specifica. Bolletino - Societa Medico Chirurgica Pavia 1933 51 : 1111 6.
8. Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 2002 71 : 533 54.
9. Tischler AS. The rat adrenal medulla. Toxicol Pathol 1989 17 : 330 2.
10. Rajaofetra N, Passagia JG, Marlier L et al. Serotoninergic, noradrenergic, and peptidergic innervation of Onuf's nucleus of normal and transected spinal cords of baboons (Papio papio). J Comp Neurol 1992 318 : 1 17.
11. Thor KB, Morgan C, Nadelhaft I et al. Organization of afferent and efferent pathways in the pudendal nerve of the female cat. J Comp Neurol 1989 288 : 263 79.
12. Marson L. Identification of central nervous system neurons that innervate the bladder body, bladder base, or external urethral sphincter of female rats: a transneuronal tracing study using pseudorabies virus. J Comp Neurol 1997 389 : 584 602.
13. Morrison J, Steers WD, Brading AF et al. Neurophysiology and neuropharmacology. In : Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence. Plymouth : Plymbridge Distributiors Ltd, 2005 : 363 413.
14. de Groat WC, Yoshimura N. Pharmacology of the lower urinary tract. Annu Rev Pharmacol Toxicol 2001 41 : 691 721.
15. Yoshiyama M, Roppolo JR, Thor KB, de Groat WC. Effects of LY274614, a competitive NMDA receptor antagonist, on the micturition reflex in the urethane-anaesthetized rat. Br J Pharmacol 1993 110 : 77 86.
16. Yoshiyama M, Roppolo JR, de Groat WC. Effects of LY215490, a competitive alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor antagonist, on the micturition reflex in the rat. J Pharmacol Exp Ther 1997 280 : 894 904.
17. Danuser H, Thor KB. Spinal 5-HT2 receptor-mediated facilitation of pudendal nerve reflexes in the anaesthetized cat. Br J Pharmacol 1996 118 : 150 4.
18. Danuser H, Bemis K, Thor KB. Pharmacological analysis of the noradrenergic control of central sympathetic and somatic reflexes controlling the lower urinary tract in the anesthetized cat. J Pharmacol Exp Ther 1995 274 : 820 5.
19. Thor KB. Targeting serotonin and norepinephrine receptors in stress urinary incontinence. Int J Gynaecol Obstet 2004 86 (Suppl. 1 S38 52.
20. Stahl S, Briley M. Understanding pain in depression. Hum Psychopharmacol 2004 19 (Suppl. 1 S9 S13.
21. Fields HL, Heinricher MM, Mason P. Neurotransmitters in nociceptive modulatory circuits. Annu Rev Neurosci 1991 14 : 219 45.
22. Briley M. New hope in the treatment of painful symptoms in depression. Curr Opin Investig Drugs 2003 4 : 42 5.
23. Ren K, Dubner R. Descending modulation in persistent pain: an update. Pain 2002 100 : 1 6.
24. Stahl SM. Basic psychopharmacology of antidepressants, part 1: antidepressants have seven distinct mechanisms of action. J Clin Psychiatry 1998 59 (Suppl. 4 5 14.
25. Hampel C, Wienhold D, Benken N et al. Definition of overactive bladder and epidemiology of urinary incontinence. Urology 1997 50 (6A Suppl 4 14.
26. Fultz NH, Burgio K, Diokno AC, Kinchen KS et al. Burden of stress urinary incontinence for community-dwelling women. Am J Obstet Gynecol 2003 189 : 1275 82.
27. Norton PA, Zinner NR, Yalcin I, Bump RC. Duloxetine vs. placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol 2002 187 : 40 8.
28. Dmochowski RR, Miklos JR, Norton PA et al. Duloxetine vs. placebo for the treatment of North American women with stress urinary incontinence. J Urol 2003 170 (4 Pt 1 1259 63.
29. Millard RJ, Moore K, Rencken R et al. Duloxetine vs. placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial. BJU Int 2004 93 : 311 8.
30. van Kerrebroeck P, Abrams P, Lange R et al. Duloxetine vs. placebo in the treatment of European and Canadian women with stress urinary incontinence. BJOG 2004 111 : 249 57.
31. Greenberg PE, Kessler RC, Birnbaum HG et al. The economic burden of depression in the United States: how did it change between 1990 and 2000 J Clin Psychiatry 2003 64 : 1465 75.
32. Gumnick JF, Nemeroff CB. Problems with currently available antidepressants. J Clin Psychiatry 2000 61 (Suppl. 10 5 15.
33. Detke MJ, Lu Y, Goldstein DJ et al. Duloxetine 60 mg once daily dosing vs. placebo in the acute treatment of major depression. J Psychiatr Res 2002 36 : 383 90.
34. Detke MJ, Lu Y, Goldstein DJ et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002 63 : 308 15.
35. Detke MJ, Wiltse CG, Mallinckrodt CH et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004 14 : 457 70.
36. Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 2002 63 : 225 31.
37. Goldstein DJ, Lu Y, Detke MJ et al. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004 24 : 389 99.
38. Nemeroff CB, Schatzberg AF, Goldstein DJ et al. Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 2002 36 : 106 32.
39. Raskin J, Goldstein DJ, Mallinckrodt CH, Ferguson MB. Duloxetine in the long-term treatment of major depressive disorder. J Clin Psychiatry 2003 64 : 1237 44.
40. Maizels M, McCarberg B. Antidepressants and antiepileptic drugs for chronic non-cancer pain. Am Fam Physician 2005 71 : 483 90.
41. Dworkin RH, Backonja M, Rowbotham MC et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol 2003 60 : 1524 34.
42. Leo RJ, Barkin RL. Antidepressant use in chronic pain management: is there evidence of a role for duloxetine Prim Care Companion J Clin Psychiatry 2003 5 : 118 23.
43. McQuay HJ, Tramer M, Nye BA et al. A systematic review of antidepressants in neuropathic pain. Pain 1996 68 : 217 27.
44. Ross EL. The evolving role of antiepileptic drugs in treating neuropathic pain. Neurology 2000 55 (Suppl. 1 S41 6.
45. Wernicke JF, Pritchett YL, D'Souza DN et al. Duloxetine in the management of diabetic peripheral neuropathic pain. Neurology 2006 67 : 1411 20.
46. Goldstein DJ, Lu Y, Detke MJ et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005 116 : 109 18.
47. Raskin J, Pritchett YL, Wang F et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005 6 : 346 56.
48. Raskin J, Wang F, Pritchett YL, Goldstein DJ. Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month Open-Label Safety Study. Pain Med 2006 7 : 373 85.
49. Hurley DJ, Turner CL, Yalcin I et al. Duloxetine for the treatment of stress urinary incontinence in women: an integrated analysis of safety. Eur J Obstet Gynecol Reprod Biol 2005 125 : 120 8.
50. Hudson JI, Wohlreich MM, Kajdasz DK et al. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Hum Psychopharmacol 2005 20 : 327 41.
51. Ueda N, Yoshimura R, Shinkai K et al. Higher plasma 5-hydroxyindoleacetic acid levels are associated with SSRI-induced nausea. Neuropsychobiology 2003 48 : 31 4.
52. Burrows GD, Maguire KP, Norman TR. Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review. J Clin Psychiatry 1998 59 (Suppl. 14 4 7.
53. Versiani M, Amin M, Chouinard G. Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder. J Clin Psychopharmacol 2000 20 : 28 34.
54. Viktrup L, Pangallo BA, Detke MJ, Zinner NR. Urinary side effects of duloxetine in the treatment of depression and stress urinary incontinence. Prim Care Companion J Clin Psychiatry 2004 6 : 65 73.
55. Viktrup L, Perahia DG, Tylee A. Duloxetine treatment of stress urinary incontinence in women does not induce mania or hypomania. Prim Care Companion J Clin Psychiatry 2004 6 : 239 43.
56. Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 1999 19 : 67 85.
57. Delgado PL, Brannan SK, Mallinckrodt CH et al. Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. J Clin Psychiatry 2005 66 : 686 92.